1. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia
- Author
-
Mariko Murakami, Makoto Ujihara, Sachiko Takagi, Yasushi Tanaka, Akio Ohta, Takuyuki Katabami, Tomoya Matsui, Mariko Higa, Suzuko Kobayashi, and Takamasa Ichijo
- Subjects
Male ,Type 2 diabetes ,Biochemistry ,Gastroenterology ,chemistry.chemical_compound ,High-density lipoprotein ,Prospective Studies ,Rosuvastatin Calcium ,Creatine Kinase ,Hypolipidemic Agents ,Aged, 80 and over ,Sulfonamides ,biology ,Anticholesteremic Agents ,General Medicine ,Middle Aged ,Female ,lipids (amino acids, peptides, and proteins) ,Lipoproteins, HDL ,medicine.drug ,Adult ,medicine.medical_specialty ,Renal function ,Carbohydrate metabolism ,Young Adult ,Internal medicine ,medicine ,Humans ,Rosuvastatin ,Triglycerides ,Aged ,Dyslipidemias ,business.industry ,Cholesterol, HDL ,Biochemistry (medical) ,nutritional and metabolic diseases ,Type 2 Diabetes Mellitus ,Cholesterol, LDL ,Cell Biology ,medicine.disease ,Fluorobenzenes ,Glucose ,Pyrimidines ,Endocrinology ,Diabetes Mellitus, Type 2 ,chemistry ,biology.protein ,Creatine kinase ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,Lipoprotein - Abstract
Objective To analyse the efficacy of low-dose rosuvastatin for treating hypo high-density lipoprotein (HDL) cholesterolaemia in patients with type 2 diabetes and dyslipidaemia. Methods Patients with HDL-cholesterol (C) Results Out of 49 patients, all lipid parameters other than TG were significantly improved at 3 and 6 months. At 3 months, 83.3% of patients had achieved the target LDL-C level. Among nonlipid parameters, no changes were observed except for estimated glomerular filtration rate, which was improved by + 5.2% and + 9.6% at 3 and 6 months, respectively. Conclusions Low-dose rosuvastatin was effective in improving hypo-HDL cholesterolaemia and may have renoprotective effects.
- Published
- 2014
- Full Text
- View/download PDF